COMMUNIQUÉS West-GlobeNewswire

Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update
26/03/2026
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its [...]
CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings
26/03/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today announced the filing of two new patent applications that further expand the [...]
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
26/03/2026
TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath ® as a Stand-Alone Device for Drug-Delivery in [...]
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
26/03/2026
BETHESDA, Md., March 26, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
BiomX Launches Security Subsidiary in Israel and Will Initially Invest Over $3 million In Its Operations
26/03/2026
Initiative marks entry into Israel’s rapidly growing autonomous AI defense, firefighting and first response activities NETANYA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) today announced [...]
Notice convening the Annual General Meeting in BioPorto A/S
26/03/2026
26 March 2026 Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on [...]
FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG Inhibition
26/03/2026
PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers Preclinical data show high potency across multiple solid tumor cell lines and in vivo models, including those resistant [...]
Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026
26/03/2026
Oslo, 26 March 2026 - The Board of Directors hereby calls for the Annual General Meeting of Zelluna ASA at 09:00 CEST on 23 April 2026. The General Meeting will be held electronically and all documents related to the [...]
BioPorto announces the Annual Report for 2025
26/03/2026
March 26, 2026 Announcement no. 04 BioPorto announces the Annual Report for 2025 Copenhagen, Denmark, March 26, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or company) (CPH:BIOPOR), today announced [...]
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
26/03/2026
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS ) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based [...]
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
25/03/2026
TORONTO, ONTARIO, March 25, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”), a life science company focused on the development of natural, plant-based active [...]
ATI Advisory Releases New Analysis of MSSP ACO Episodes, Highlighting Concentrated Financial Exposure and Opportunity Under LEAD
25/03/2026
ATI released a data brief analyzing 1.19 million MSSP shadow bundles, finding that Medicare ACO spending is concentrated in specific medical conditions and post-acute settings—creating a clear opportunity for [...]
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
25/03/2026
Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced [...]
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation
25/03/2026
SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology [...]
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
26/03/2026
Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million) Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of [...]
XORTX Announces Share Consolidation
25/03/2026
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
25/03/2026
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in [...]
Lifeward Successfully Closes on Strategic Partnership with Oramed
25/03/2026
HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people [...]
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
25/03/2026
Initiation of Phase 1 proof-of-mechanism study of EQ504 planned for mid-2026, with data expected approximately six months thereafter Cash and cash equivalents, inclusive of the March 2026 financing, expected to fund [...]

Pages